Cancer Incidence Varied Among Organ Transplant Recipients

A study of over 622,000 patients found lung transplant recipients faced the highest rates of posttransplant malignancy.

Updated on Oct. 12, 2026 in Cancer

Cancer Incidence Varied Among Organ Transplant Recipients

Live Poll

Do you trust that current transplant aftercare sufficiently monitors patients for long-term cancer risks?

Researchers analyzed 622,330 organ transplant patients to identify cancer incidence rates among heart, kidney, liver, and lung recipients. The study found that 8% of patients were diagnosed with at least one cancer, with lung transplant recipients exhibiting the highest risk for solid tumors.

Why it matters

Higher cancer rates observed in lung and heart transplant recipients may stem from the more intense immunosuppressive therapy required for those procedures. This research highlights the need for tailored long-term monitoring for high-risk patients following surgery.

A study of 622,330 patients identified nonmelanoma skin cancer as the most frequent malignancy at 54.9% of cases. Five-year survival rates varied by organ, ranging from 89% for pancreas recipients to 60% for those who received lung transplants.

The players

Transplant Recipients

These individuals are patients who have undergone the surgical replacement of a vital organ including the heart, kidney, liver, or lung.

The details

Lung transplant recipients showed an incidence rate ratio of 2.01 for solid tumors and 2.91 for posttransplant lymphoproliferative disorder compared to kidney transplant patients. Across the study population, incidences of bladder, colorectal, genital, and lung cancers increased over the 10-year follow-up period.

Patients received transplants between 2000 and 2023.
U.S. annual solid organ transplants grew from 29,768 in 2013 to 46,750 in 2024.
The follow-up period for malignancy diagnosis extended up to 10 years.

Health Landscape

This study follows the research trajectory established by the National Institutes of Health organ transplantation research initiatives. It expands on existing knowledge regarding long-term clinical outcomes in a period when U.S. annual solid organ transplants have increased by over 50 percent.

Patients who have undergone heart or lung transplants should discuss specific cancer screening needs with their medical teams due to the higher intensity of required immunosuppression. This data may lead to personalized long-term surveillance plans that improve outcomes for high-risk transplant recipients.

The takeaway

Patients who have received transplants require consistent long-term monitoring for a variety of secondary malignancies. Understanding the relationship between specific organ types and cancer risk can help clinicians adjust immunosuppressive therapies to balance organ health with cancer prevention.